公开(公告)号：WO2010124009A2

公开(公告)日：2010-10-28

申请号：PCT/US2010/031921

申请日：2010-04-21

Applicant: SCHERING CORPORATION ,  XOMA TECHNOLOGY LTD. ,  RAMACHANDRA, Sumant ,  HUANG, Chin-Yi ,  MASAT, Linda ,  HUANG, Chao, Bai ,  BISHOP, Walter, Robert ,  TAKEUCHI, Toshihiko ,  KANTAK, Seema ,  HOROWITZ, Jo Ann ,  LADHA, Mohamed H.

Inventor： RAMACHANDRA, Sumant ,  HUANG, Chin-Yi ,  MASAT, Linda ,  HUANG, Chao, Bai ,  BISHOP, Walter, Robert ,  TAKEUCHI, Toshihiko ,  KANTAK, Seema ,  HOROWITZ, Jo Ann ,  LADHA, Mohamed H.

IPC: A61K39/395

CPC classification number: C07K16/22 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/00

Abstract: Disclosed herein are fully human antibodies and antigen-binding fragments thereof that specifically bind human VEGF and inhibit VEGF binding to VEGF-R1 and VEGF-R2, and therefore inhibit VEGF signaling. The antibodies and antigen- binding fragments disclosed herein may be used, for example, to treat angiogenesis and conditions associated with angiogenesis both in vivo and in vitro.

Abstract translation: 本文公开了完全人抗体及其抗原结合片段，其特异性结合人VEGF并抑制VEGF与VEGF-R1和VEGF-R2的结合，因此抑制VEGF信号传导。 本文公开的抗体和抗原结合片段可用于例如在体内和体外治疗血管发生和与血管发生相关的病症。

公开(公告)号：WO2009055343A3

公开(公告)日：2009-09-24

申请号：PCT/US2008080531

申请日：2008-10-20

Applicant: SCHERING CORP ,  XOMA TECHNOLOGY LTD ,  RAMACHANDRA SUMANT ,  BISHOP WALTER ROBERT ,  MASAT LINDA ,  HUANG CHAO BAI ,  TAKEUCHI TOSHIHIKO ,  KANTAK SEEMA ,  HUANG CHIN-YI

Inventor： RAMACHANDRA SUMANT ,  BISHOP WALTER ROBERT ,  MASAT LINDA ,  HUANG CHAO BAI ,  TAKEUCHI TOSHIHIKO ,  KANTAK SEEMA ,  HUANG CHIN-YI

IPC: C12P21/08

CPC classification number: C07K16/22 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00 ,  Y10S435/81

Abstract: Disclosed herein are fully human antibodies and antigen-binding fragments thereof that specifically bind human VEGF and inhibit VEGF binding to VEGF-R1 and VEGF-R2, and therefore inhibit VEGF signaling. The antibodies and antigen-binding fragments disclosed herein may be used, for example, to treat angiogenesis and conditions associated with angiogenesis both in vivo and in vitro.

Abstract translation: 本文公开了完全人抗体及其抗原结合片段，其特异性结合人VEGF并抑制VEGF与VEGF-R1和VEGF-R2的结合，因此抑制VEGF信号传导。 本文公开的抗体和抗原结合片段可用于例如在体内和体外治疗血管发生和与血管发生相关的病症。

公开(公告)号：WO2007103425A2

公开(公告)日：2007-09-13

申请号：PCT/US2007/005814

申请日：2007-03-06

Applicant: NOVARTIS AG ,  OKHAMAFE, Augustus ,  HUANG, Chin-Yi

Inventor： OKHAMAFE, Augustus ,  HUANG, Chin-Yi

CPC classification number: A61K9/08 ,  A61K9/0019 ,  A61K38/57 ,  A61K47/12 ,  A61K47/183

Abstract: The polypeptide Tissue Factor Pathway Inhibitor (TFPI) and variants thereof can be advantageously stored in a form ( e.g ., a concentrated aqueous solution) that exhibits high stability and thereafter converted ( e.g ., by mixing with a diluent) into a form that is therapeutically effective ( e.g ., in the treatment of severe Community Acquired Pneumonia) when administered parenterally ( e.g ., intravenously) to patients. The separate storage of components of pharmaceutical compositions comprising TFPI and TFPI variants provides several important advantages. The components are generally a concentrated polypeptide solution and a diluent.

Abstract translation: 多肽组织因子通路抑制剂（TFPI）及其变体可有利地以表现出高稳定性并随后转化（例如通过与稀释剂混合）形成治疗有效的形式（例如，浓缩水溶液） （例如，在严重的社区获得性肺炎的治疗中）当向患者肠胃外（例如，静脉内）施用时。 包含TFPI和TFPI变体的药物组合物的组分的单独储存提供了几个重要的优点。 组分通常是浓缩的多肽溶液和稀释剂。

公开(公告)号：WO2010124009A3

公开(公告)日：2011-01-06

申请号：PCT/US2010031921

申请日：2010-04-21

Applicant: SCHERING CORP ,  XOMA TECHNOLOGY LTD ,  RAMACHANDRA SUMANT ,  HUANG CHIN-YI ,  MASAT LINDA ,  HUANG CHAO BAI ,  BISHOP WALTER ROBERT ,  TAKEUCHI TOSHIHIKO ,  KANTAK SEEMA ,  HOROWITZ JO ANN ,  LADHA MOHAMED H

Inventor： RAMACHANDRA SUMANT ,  HUANG CHIN-YI ,  MASAT LINDA ,  HUANG CHAO BAI ,  BISHOP WALTER ROBERT ,  TAKEUCHI TOSHIHIKO ,  KANTAK SEEMA ,  HOROWITZ JO ANN ,  LADHA MOHAMED H

IPC: C07K16/22 ,  C12P21/08

CPC classification number: C07K16/22 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/00

Abstract: Disclosed herein are fully human antibodies and antigen-binding fragments thereof that specifically bind human VEGF and inhibit VEGF binding to VEGF-R1 and VEGF-R2, and therefore inhibit VEGF signaling. The antibodies and antigen- binding fragments disclosed herein may be used, for example, to treat angiogenesis and conditions associated with angiogenesis both in vivo and in vitro.

Abstract translation: 本文公开了完全人抗体及其抗原结合片段，其特异性结合人VEGF并抑制VEGF与VEGF-R1和VEGF-R2的结合，因此抑制VEGF信号传导。 本文公开的抗体和抗原结合片段可用于例如在体内和体外治疗血管发生和与血管发生相关的病症。

公开(公告)号：WO2011028962A1

公开(公告)日：2011-03-10

申请号：PCT/US2010/047753

申请日：2010-09-02

Applicant: XOMA TECHNOLOGY LTD. ,  BABUKA, Susan Joyce ,  HUANG, Chin-Yi ,  LI, Mingxiang

Inventor： BABUKA, Susan Joyce ,  HUANG, Chin-Yi ,  LI, Mingxiang

IPC: A61K39/395 ,  A61K47/00

CPC classification number: G01N30/36 ,  A61K39/39591 ,  A61K2039/507 ,  C07K16/1282 ,  G01N25/20 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/394 ,  Y02A50/401 ,  Y02A50/407 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/423 ,  Y02A50/466 ,  Y02A50/469

Abstract: This invention relates to stable formulations of multiple antibodies comprising a plurality of antibodies and an effective amount of a succinate buffer wherein the pH of the formulation is between about 4.5 and about 7.0.

Abstract translation: 本发明涉及包含多种抗体和有效量的琥珀酸盐缓冲液的多种抗体的稳定制剂，其中制剂的pH为约4.5至约7.0。

公开(公告)号：WO2007103425A3

公开(公告)日：2008-01-31

申请号：PCT/US2007005814

申请日：2007-03-06

Applicant: NOVARTIS AG ,  OKHAMAFE AUGUSTUS ,  HUANG CHIN-YI

Inventor： OKHAMAFE AUGUSTUS ,  HUANG CHIN-YI

IPC: A61K9/00 ,  A61K38/57 ,  A61K47/12 ,  A61K47/18 ,  A61P11/00

CPC classification number: A61K9/08 ,  A61K9/0019 ,  A61K38/57 ,  A61K47/12 ,  A61K47/183

Abstract: The polypeptide Tissue Factor Pathway Inhibitor (TFPI) and variants thereof can be advantageously stored in a form (e.g., a concentrated aqueous solution) that exhibits high stability and thereafter converted (e.g., by mixing with a diluent) into a form that is therapeutically effective (e.g., in the treatment of severe Community Acquired Pneumonia) when administered parenterally (e.g., intravenously) to patients. The separate storage of components of pharmaceutical compositions comprising TFPI and TFPI variants provides several important advantages. The components are generally a concentrated polypeptide solution and a diluent.

Abstract translation: 多肽组织因子通路抑制剂（TFPI）及其变体可有利地以表现出高稳定性并随后转化（例如通过与稀释剂混合）形成治疗有效的形式（例如，浓缩水溶液） （例如，在严重的社区获得性肺炎的治疗中）当向患者肠胃外（例如，静脉内）施用时。 包含TFPI和TFPI变体的药物组合物的组分的单独储存提供了几个重要的优点。 组分通常是浓缩的多肽溶液和稀释剂。